In our final episode of the series we are joined by Dr Nadza Tokaca from The Royal Marsden Hospital, London, who discussuses First-Line Strategies for Pleural and Peritoneal Mesothelioma. We will also hear from Dr Dean Fennell from The University of Leicester, Leicestershire, who will present on Strategies for Pre-Treated Mesothelioma: Current Standards and Future Directions. It is co-chaired by Prof Raffaele Califano, from The Christie, Manchester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Dr Anna Minchom from the Institute of Cancer Research and the Royal Marsden Hospital, London, who discusses Targeting RET and MET Positive Advanced NSCLC. We will also hear from Prof Alastair Greystoke from the Northern Centre for Cancer Care, Newcastle, who will present on Targeting EGFR exon-20, NTRK and HER2 Positive Advanced NSCLC. It is co-chaired by Prof Samreen Ahmed, from University Hospitals Leicester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Dr Tanya Ahmad from University College London Hospitals, who discusses Treatment of BRAF-Mutant NSCLC. We will also hear from Dr Helen Adderley from The Christie, Manchester, who will present on Genomic Screening for Lung Cancer: Treatment of KRAS-Mutant NSCLC. It is co-chaired by Prof Raffaele Califano, from The Christie, Manchester. Our two guest speakers engage in a disucssion to close the episode.

Happy New Year! This month we will hear from Dr Yvonne Summers from The Christie, Manchester, who will provide insight on Standard Stratergies for Advanced ALK and ROS1-Mutant NSCLC. We are also joined by our co-chair, Prof Samreen Ahmed from University Hospitals Leicester, who presents on What’s New in the Field of ALK and ROS1-Mutant NSCLC. It is co-chaired by Prof Raffaele Califano, from The Christie, Manchester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by our co-chair, Prof Samreen Ahmed from University Hospitals Leicester, who presents on Standard Stratergies for Advanced EGFR-Mutant Stage IV NSCLC. We will also hear from Dr Carles Escriu from The Clatterbridge Cancer Centre, Liverpool, who will provide insight on What’s New in the Field of EGFR-Mutant Stage IV NSCLC. It is co-chaired by Prof Raffaele Califano, from The Christie, Manchester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Dr Dionysis Papadatos-Pastos from University College London Hospitals, who discusses The Role of First-Line Immunotherapy or Chemoimmunotherapy for Advanced NSCLC. We will also hear from Dr Tim Benepal from St Georges University Hospitals, NHS FT, who will present on Second-Line Therapies for Advanced NSCLC. It is co-chaired by Prof Samreen Ahmed, from University Hospitals Leicester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Prof Corinne Faivre-Finn from The Christie, Manchester, who discusses Management of Limited-Stage Small Cell Lung Cancer. We will also hear from our co-chair Prof Raffaele Califano from The Christie and Manchester University Hospital, who will present on Management of Extensive-Stage Small Cell Lung Cancer - Chemo-Immunotherapy and Beyond. It is co-chaired by Prof Samreen Ahmed, from University Hospitals Leicester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Dr Fiona McDonald from the Royal Marsden Hospital, London, who discusses The Role of Concurrent Chemotherapy Followed by Durvalumab. We will also hear from Dr Shobhit Baijal from The University Hospital Birmingham NHS Trust, who will present on The Role of Perioperative Immunotherapy for Early-Stage/Locally Advanced NSCLC. It is co-chaired by Prof Samreen Ahmed, from University Hospitals Leicester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Dr Tom Newsom-Davis from Chelsea and Westminster Hospital, London, who discusses The Role of Adjuvant Targeted Therapies and Immunotherapy for Completely Resected Early-Stage NSCLC. It is co-chaired by Prof Raffaele Califano, from The Christie, Manchester. Our two speakers engage in a disucssion to close the episode.

This month we are joined by Mr Felice Granato from Wythenshawe Hospital, Manchester, who discusses The Role of Surgery for Early-Stage NSCLC. We will also hear from Dr John Conibear from Barts Cancer Centre, London, who will present on the Role of Radical Radiotherapy (Standard or SABR) for NSCLC. It is co-chaired by Prof Samreen Ahmed, from University Hospitals Leicester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Prof Keith Kerr from The University of Aberdeen, who discusses The Role of the Pathologist for the Diagnosis and the Molecular Subtyping of Lung Cancer. We will also hear from Dr Helene Schlecht from the Manchester Centre for Genomic Medicine, who will present on Genomic Screening for Lung Cancer: The Role of Next Generation Sequencing. It is co-chaired by Prof Raffaele Califano, from The Christie, Manchester. Our two guest speakers engage in a disucssion to close the episode.

This month we are joined by Dr Haval Balata, from Wythenshawe Hospital in Manchester, who discusses The Role of Screening for Lung Cancer. We will also hear from Prof Phil Crosbie, from The University of Manchester, who will present on The Challenges to Implementing Biomarker- Based Screening and MRD Detection. It is co-chaired by Prof Samreen Ahmed, from University Hospitals Leicester. Our two guest speakers engage in a disucssion to close the episode.